[Edaily Reporter Park Jeong-soo] #NeoImmuneTech announced on the 10th that it has decided to conduct a 1.5 billion won rights offering to secure operating funds (funds for acquiring all rights to Endari in North America). The capital increase will be conducted via a third-party allotment, with the allottee being Emmaus Life Sciences of the United States. The new shares consist of 683,960 common shares, and the issue price is 2,220 won (discount rate: -10%). The new shares are scheduled to be listed on the 6th of next month.
Disclosure Plus
NeoImmunetech Decides on 1.5 Billion Won Third-Party Allotment Capital Increase
Park Jung-Soo
2026-06-10 16:50:02
Economy
Corporation
IT·Science
Economy
Securing Cash Flow by Mining Cryptocurrency with Wasted Energy… On the Path to Becoming a Unicorn
Energy deep-tech companies, which face long roadmaps to commercialization, are finding a breakthrough through Bitcoin mining. Their strategy is to secure initial cash flow using surplus electricity an…
Corporation
HARIM Co., Ltd. to Split 'Real Estate Development and Food Businesses'… New Company, Harim Foods, to Be Established
#Harim Industries, a wholly-owned subsidiary of Harim Holdings Co., Ltd., is moving forward with a spin-off to separate its real estate development and food business divisions. This move is seen as a …
IT·Science
SLSBio(Specialty Lab Solution Bio) Co., Ltd., Which Challenged Delisting Decision, Sees Liquidation Trading Suspended Following Application for Preliminary Injunction
SLSBio(Specialty Lab Solution Bio) Co., Ltd(246250)has filed a motion with the court for a provisional injunction to suspend the Korea Exchange’s delisting decision. As a result, the delisting procedu…
